• Gastrin I: Precision Tools for Human Gastric Acid Pathway Re

  2026-05-25

  Human Gastrin I peptide from APExBIO unlocks robust, reproducible modeling of gastric acid secretion in advanced in vitro systems—especially hiPSC-derived intestinal organoids. This guide details optimized workflows, troubleshooting strategies, and key innovations driving next-generation gastrointestinal physiology studies.

• Brefeldin A in Cancer and Endothelial Research: Applied Work

  2026-05-25

  Brefeldin A (BFA) redefines ER stress and apoptosis assays by enabling precise dissection of protein trafficking and cell death pathways. This guide delivers actionable workflows, troubleshooting strategies, and translational insights, highlighting APExBIO’s trusted supply and the latest biomarker-informed research.

• HyperScribe™ T7 High Yield RNA Synthesis Kit: Mechanisms & B

  2026-05-24

  The HyperScribe™ T7 High Yield RNA Synthesis Kit enables rapid, high-yield in vitro RNA synthesis using T7 RNA polymerase. This kit supports versatile applications, including capped and biotinylated RNA production for advanced research. Its quantitative performance and workflow integration are supported by published benchmarks and rigorous peer-reviewed evidence.

• Polyether Ionophore Toxicity: Mechanisms and Implications fo

  2026-05-23

  This review provides a comprehensive analysis of the clinical and molecular mechanisms underlying polyether ionophore toxicity in animals, with a focus on Salinomycin and related compounds. The findings highlight the dual significance of these agents—as both toxicants in veterinary contexts and potential anti-cancer candidates—by elucidating their structure, ion transport mechanisms, and cellular effects.

• ERAD-Hijacking ERADECs: A Platform for TM Protein Degradatio

  2026-05-22

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a novel small-molecule platform that co-opts the ER-associated degradation (ERAD) pathway to selectively degrade transmembrane (TM) proteins. This innovation overcomes longstanding barriers in targeted protein degradation, enabling highly efficient elimination of membrane targets and broadening the scope for drug discovery and membrane protein research.

• GSK J4 HCl: JMJD3 Inhibitor Workflows in Epigenetic Research

  2026-05-22

  GSK J4 HCl stands out as a high-performance JMJD3 inhibitor, propelling research into histone methylation, immune modulation, and cancer biology. This article demystifies advanced workflows and troubleshooting strategies, transforming GSK J4 HCl from a chemical tool into a reliable engine for translational epigenetics.

• Screening MMV Compounds Reveals Antifungal Activity Against

  2026-05-21

  This study systematically screened the MMV Pandemic Response Box to identify compounds with in vitro activity against multidrug-resistant (MDR) bacterial and fungal clinical isolates, including Candida species. The findings highlight new antifungal candidates, demonstrate robust methodology for resistance screening, and inform future translational research on Candida infection management.

• GPER1 as a Chemopreventive Target in Prostate Cancer Progres

  2026-05-21

  This study establishes G-protein coupled estrogen receptor 1 (GPER1) as a critical suppressor of prostate cancer (PCa) progression, particularly at the high-grade prostatic intraepithelial neoplasia (HGPIN) stage. By integrating human samples, animal models, and mechanistic in vitro assays, the authors demonstrate that GPER1 activation halts tumorigenic transition, highlighting its therapeutic relevance.

• Stattic in STAT3 Pathway Research: Beyond Cancer to Inflamma

  2026-05-20

  Explore how Stattic, a potent STAT3 inhibitor, reveals new mechanistic insights in both cancer biology and inflammatory skin disorders. This article uniquely bridges oncology and immunology, leveraging recent breakthroughs to guide advanced experimental design.

• Aminopeptidase Inhibitors Reveal Angiotensin III as Active B

  2026-05-20

  This study demonstrates that Bestatin hydrochloride (Ubenimex), an inhibitor of aminopeptidase B, dramatically enhances angiotensin-evoked neuronal activity in the rat brain, supporting the hypothesis that angiotensin II must be converted to angiotensin III to exert central effects. These findings clarify peptide processing in neuroendocrine signaling and inform experimental approaches to cardiovascular and neurobiological research.

• Faropenem Sodium in Resistance Research: Mechanisms, Risks &

  2026-05-19

  Explore how Faropenem sodium, a penem antibiotic, enables advanced resistance research by combining broad-spectrum activity with mechanistic insights. This article critically examines its impact on antimicrobial resistance and provides actionable guidance for assay selection.

• Advancing Translational Immunotoxicology: Strategic ROS Assa

  2026-05-19

  Explore how advanced ROS detection—anchored by the APExBIO Reactive Oxygen Species (ROS) Assay Kit (DHE)—enables translational researchers to unravel redox-driven immunotoxicity mechanisms and design targeted interventions. Drawing on mechanistic insights, recent immunotoxicology findings, and best-practice workflows, this thought-leadership article delivers actionable guidance that bridges molecular discovery and preclinical application.

• STAT5B Overexpression Restores Myelin in Parkinson’s Models

  2026-05-18

  Li et al. (2025) reveal that oligodendrocyte-specific STAT5B overexpression mitigates myelin impairment and dopaminergic neuron loss in Parkinson’s disease (PD) models. This work uncovers a key epigenetic axis—DNMT3A-STAT5B-MBP—linking methylation-driven transcriptional repression to PD-associated myelin pathology, with broad implications for neurodegeneration research.

• Toremifene vs Tamoxifen in Advanced Breast Cancer: Evidence

  2026-05-18

  This Cochrane meta-analysis rigorously compares the efficacy and safety of toremifene and tamoxifen for advanced breast cancer. The review finds similar clinical outcomes between the two selective estrogen receptor modulators, informing therapeutic decision-making in hormone receptor-positive disease.

• TCF25 Orchestrates Lysosomal Cell Death Under Glucose Starva

  2026-05-17

  Ren et al. (2025) identify TCF25 as a critical nutrient sensor that modulates lysosomal acidification and triggers cell death via ferritinophagy in glucose-starved cells. These findings clarify the molecular link between metabolic adaptation and lysosome-dependent cell death, suggesting new avenues for targeting metabolic vulnerabilities in disease.

14840 records 8/990 page Previous Next First page 上5页 678910 下5页 Last page